We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Menlo Therapeutics Inc | NASDAQ:MNLO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.35 | 1.36 | 1.37 | 0 | 01:00:00 |
| | |
Per Share of
Common Stock |
| |
Total
|
| ||||||
Public offering price | | | | $ | | | | | $ | | | ||
Underwriting discounts and commissions(1) | | | | $ | | | | | $ | | | ||
Proceeds to Menlo Therapeutics Inc., before expenses | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-5 | | | |
| | | | S-8 | | | |
| | | | S-10 | | | |
| | | | S-11 | | | |
| | | | S-12 | | | |
| | | | S-14 | | | |
| | | | S-18 | | | |
| | | | S-25 | | | |
| | | | S-25 | | | |
| | | | S-26 | | | |
| | | | S-26 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 29 | | | |
| | | | | 31 | | | |
| | | | | 31 | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share before this offering, as of March 31, 2020, after giving effect to the conversion of the CSRs issued in connection with the Merger on April 6, 2020 and before giving effect to this offering
|
| | | $ | | | | | | | | | |
|
Increase in net tangible book value per share attributable to investors in this
offering |
| | | $ | | | | | | | | | |
|
Pro forma net tangible book value per share after offering
|
| | | | | | | | | $ | | | |
|
Dilution in pro forma tangible book value per share to new investors
|
| | | | | | | | | $ | | | |
Underwriter
|
| |
Number of Shares
|
| |||
Cowen and Company, LLC
|
| | | | | | |
Piper Sandler & Co.
|
| | | | | | |
LifeSci Capital LLC
|
| | | | | | |
Total
|
| | | | | |
| | | | | | | | |
Total
|
| |||||||||
| | |
Per Share
|
| |
Without
Exercise |
| |
With Full
Exercise |
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discount
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | | | $ | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 29 | | | |
| | | | | 31 | | | |
| | | | | 31 | | |
| | |
Year Ended December 31,
|
| |
Nine Months
Ended September 30, 2018 |
| ||||||||||||||||||
(in thousands)
|
| |
2017
|
| |
2016
|
| |
2015
|
| |||||||||||||||
Deficiency of earnings available to cover fixed charges
|
| | | $ | 29,076 | | | | | $ | 14,068 | | | | | $ | 4,608 | | | | | $ | 33,852 | | |
1 Year Menlo Therapeutics Chart |
1 Month Menlo Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions